Professor Allen Chan
Keynote Speaker

Professor Chan is serving as a Professor at the Department of Chemical Pathology of The Chinese University of Hong Kong. Allen’s main research interest is on the development of innovative diagnostic approaches based on circulating DNA analysis. He developed the first digital PCR based method for the detection of EGFR mutations in the plasma of lung cancer patients. He is a co-inventor of the noninvasive Down syndrome test and developed numerous approaches for the detection of cancers. He is an inventor of over 40 patents families on molecular diagnostics. He has just finished a prospective study on the screening of early nasopharygeal carcinoma in 20,000 asymptomatic men using liquid biopsy.

In addition to research, Allen is also passionate about teaching and received a total of four Teacher of the Year awards from the Faculty of Medicine, CUHK.

Associate Professor Kevin Spring
Keynote Speaker

Associate Professor Spring holds an academic appointment (Medical Oncology) with Western Sydney University, is a Centre for Oncology Education and Research Training (CONCERT) Centre Fellow and Group Leader at the Ingham Institute for Applied Medical Research at Liverpool Hospital. He is also a conjoint Associate Professor at the University of NSW.

Since gaining his PhD from the University of Queensland in 1997 he has made substantial contributions toward defining the serrated neoplasia pathway in colorectal cancer; established that BRAF mutation was highly associated with methylation (CIMP) in these tumours (GUT 2004) and that sessile serrated adenomas were the precursors of MSI-H cancers (Gastroenterology 2006). He has also made significant findings in the DNA damage field, with publications in Nature (1997), Nature Genetics (2000, 2002), and was the first to generate an Atm missense knockin mutant mouse, demonstrating cancer predisposition in AT heterozygotes (Nature Genetics 2002).

His more recent research interests focus on the clinical utility of blood-based “liquid biopsy” involving circulating tumour cells (CTCs) and ctNAs. He is a foundation member of the Centre for CTC Diagnostics and Research (CCDR) at the Ingham Institute, and is the founding convenor for the Thomas Ashworth CTC & Liquid Biopsy Symposium. His research is centered on the development of predictive and prognostic biomarkers (especially microRNA) for patient stratification and real-time monitoring of treatment response in the precision oncology setting.

About the National Conference

The National Histology Conference in Australia commenced in 2003. Talks between the Victorian and New South Wales histology groups primarily led to the inaugural conference in Sydney. Since that first conference, the states with organised histology groups notionally agreed to hold the conference every two years rotating through those states.

2003 Sydney, NSW
2005 Melbourne, VIC
2006 Gold Coast, QLD
2009 Adelaide, SA
2011 Sydney, NSW
2013 Melbourne, VIC
2015 Brisbane, QLD

The event has grown in stature and professionalism with the venues, presenters and social engagements continuing to drive the conference to new levels of sophistication and probity.

This conference explores the potential for the histology groups to venture to states currently without organised histology groups. This provides one further step in the evolution of histology meetings by broadening to yet to be explored states and territories on a national level.

The Histology Group of Victoria will be the host of the conference, but unlike other National Histology Conferences will be joined by all states to create a more national approach to the first neutral location.

Conference Managers

Please contact the team at Conference Design with any questions regarding the conference.